A Pilot Study: High Versus Low Oxytocin Dosing for Induction of Labor in Pregnant Patients With Obesity (HILIO-PILOT)
Primary Purpose
Pregnant Patients With Obesity
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
High-dose oxytocin
Low-dose oxytocin
Sponsored by

About this trial
This is an interventional treatment trial for Pregnant Patients With Obesity focused on measuring Oxytocin, Pregnant patients with obesity, Induction of labor
Eligibility Criteria
Inclusion Criteria:
- Nulliparity
- Maternal age >18 years
- Gestational age ≥37w0d
- Induction of labor, defined as initiation of labor with medication or intracervical Foley catheter in a patient without observed spontaneous cervical change and <6 contractions per hour (average of one contraction every 10 minutes) at the time of initial presentation. Women with prelabor rupture of membranes (PROM) can be included if the other criteria are also met with regards to cervical dilation and contractions.
- Singleton gestation
- Cephalic presentation
- Indication for oxytocin use in the first stage of labor
- No contraindication to labor or vaginal delivery
- Pre-pregnancy BMI ≥30 kg/m2 based on patient report and confirmed by pre-pregnancy or first trimester weight as recorded in the medical record
- Cervical dilation ≤4 cm at time of initiation of induction
Exclusion Criteria:
- Fetal demise
- Major fetal congenital malformation or known chromosomal abnormality
- Prior uterine surgery (e.g., cesarean, myomectomy)
- Non-reassuring fetal wellbeing as indication for induction
- Intraamniotic infection suspected or diagnosed prior to randomization
- Non-English
- Multifetal gestation
- Gestational age <37 weeks
- Spontaneous labor
- Cervical dilation > 4 cm at initiation of induction
- Initiation of oxytocin in the second stage of labor
- Use of oxytocin prior to randomization or planned use of oxytocin with foley catheter for cervical ripening
- Fetal malpresentation
- Estimated fetal weight >4500 g in a patient with diabetes, or estimated fetal weight >5000 g in a non-diabetic patient
- Abnormal placentation (e.g. previa, suspected placenta accreta spectrum)
- Physician/provider or patient refusal
Sites / Locations
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
High-dose oxytocin regimen
Low-dose oxytocin regimen
Arm Description
Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
Outcomes
Primary Outcome Measures
Number of Participants Delivered by Cesarean
Secondary Outcome Measures
Indication for Cesarean Delivery
Primary indication for cesarean delivery as recorded by the primary surgeon in the medical record
Duration of Time From Start of Induction to Delivery
Time from start of induction with medication or Foley catheter until delivery
Duration of the First Stage of Labor
Time from start of labor to complete dilation
Occurrence of Tachysystole
Defined as more than 5 contractions in 10 minutes averaged over 30 minutes
Incidence of Uterine Rupture
Defined as a complete disruption of all uterine layers including serosa
Incidence of Clinical Chorioamnionitis
Defined based on clinical diagnosis as documented by the clinical care team
Incidence of Postpartum Maternal Infectious Morbidity
Defined as a composite outcome of endomyometritis, puerperal sepsis, or surgical site infection as documented in the the clinical record
Incidence of Maternal Death
Incidence of Immediate Postpartum Hemorrhage
Defined as >1000 mL of blood loss within 24 hours of delivery
Incidence of Maternal Blood Transfusion
Defined as need for blood transfusion
Incidence of Maternal ICU Admission
Incidence of Composite Neonatal Morbidity Outcomes
Apgar score <5 at 5 min, arterial cord pH <7.0 or base deficit >12 mmol/dL, perinatal death
Incidence of NICU Admission
Maternal Length of Stay
Duration of hospitalization for delivery
Neonatal Length of Stay
Duration of birth hospitalization
Perception of the Labor, Birth, and Postpartum Experience
Patient perception as measured using the validated Childbirth Perception Scale. This is a 12-item instrument developed to assess a patient's perception of the labor and delivery experience. Each item is formatted on a four-point scale ranging from 0 to 3. The overall range in total score is 1-36 with higher scores indicating a less positive perception.
Labor Agentry Score
Patient perception of labor agentry as measured using validated Labor Agentry Scale. This 29-item tool was developed to assess a patient's expectancies and experiences with control in labor. Each item is scored 1 to 7. Overall total score can range from 29-201 with higher scores indicated greater perceived control during childbirth.
Full Information
NCT ID
NCT05289869
First Posted
February 25, 2022
Last Updated
February 3, 2023
Sponsor
Ohio State University
1. Study Identification
Unique Protocol Identification Number
NCT05289869
Brief Title
A Pilot Study: High Versus Low Oxytocin Dosing for Induction of Labor in Pregnant Patients With Obesity
Acronym
HILIO-PILOT
Official Title
The HILIO Trial: High vs. Low Oxytocin Dosing for Induction of Labor in Pregnant Patients With Obesity- PILOT STUDY
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
April 6, 2022 (Actual)
Primary Completion Date
September 18, 2022 (Actual)
Study Completion Date
October 28, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ohio State University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Pregnant patients with obesity are more likely to undergo induction of labor and have a higher risk of failed induction compared to patients with normal weight. The association between maternal obesity and labor dysfunction leading to cesarean delivery is poorly understood. Oxytocin is the mostly common medication used in induction of labor, yet optimal dosing of this medication is unknown. Studies have suggested that patients with obesity may be less responsive to oxytocin. This trial will compare a high and low dose oxytocin dosing regimen for the induction of labor in women with obesity.
Detailed Description
This study is a pragmatic single center randomized, double blinded controlled trial. Nulliparous women with a pre-pregnancy body mass index (BMI) ≥30 kg/m2 undergoing induction of labor at ≥37 weeks' gestation will be eligible for enrollment. Women will be randomly allocated to receive oxytocin using either a high-dose or low-dose regimen. Patients, providers, and research staff will be blinded to the dosing regimen. All other aspects of obstetric management will be at the discretion of the patient's clinical care team.
Postpartum maternal, neonatal, and delivery outcomes will be collected. Postpartum data through hospital discharge will be collected from the medical record. Information about complications following hospital discharge through 6 weeks after delivery will be collected during a research follow-up telephone call performed 6-8 weeks following delivery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnant Patients With Obesity
Keywords
Oxytocin, Pregnant patients with obesity, Induction of labor
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
Participants, research staff, and clinical care providers will be blinded to the dosing regimen.
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
High-dose oxytocin regimen
Arm Type
Experimental
Arm Description
Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
Arm Title
Low-dose oxytocin regimen
Arm Type
Experimental
Arm Description
Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
Intervention Type
Drug
Intervention Name(s)
High-dose oxytocin
Intervention Description
Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
Intervention Type
Drug
Intervention Name(s)
Low-dose oxytocin
Intervention Description
Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
Primary Outcome Measure Information:
Title
Number of Participants Delivered by Cesarean
Time Frame
Until delivery
Secondary Outcome Measure Information:
Title
Indication for Cesarean Delivery
Description
Primary indication for cesarean delivery as recorded by the primary surgeon in the medical record
Time Frame
Until delivery
Title
Duration of Time From Start of Induction to Delivery
Description
Time from start of induction with medication or Foley catheter until delivery
Time Frame
From start of induction to delivery
Title
Duration of the First Stage of Labor
Description
Time from start of labor to complete dilation
Time Frame
From start of induction to delivery
Title
Occurrence of Tachysystole
Description
Defined as more than 5 contractions in 10 minutes averaged over 30 minutes
Time Frame
From start of induction to delivery
Title
Incidence of Uterine Rupture
Description
Defined as a complete disruption of all uterine layers including serosa
Time Frame
From start of induction to delivery
Title
Incidence of Clinical Chorioamnionitis
Description
Defined based on clinical diagnosis as documented by the clinical care team
Time Frame
From start of induction thorough delivery
Title
Incidence of Postpartum Maternal Infectious Morbidity
Description
Defined as a composite outcome of endomyometritis, puerperal sepsis, or surgical site infection as documented in the the clinical record
Time Frame
Within 6 weeks following delivery
Title
Incidence of Maternal Death
Time Frame
Within 6 weeks of delivery
Title
Incidence of Immediate Postpartum Hemorrhage
Description
Defined as >1000 mL of blood loss within 24 hours of delivery
Time Frame
Within 24 hours of delivery
Title
Incidence of Maternal Blood Transfusion
Description
Defined as need for blood transfusion
Time Frame
From randomization through hospital discharge up to 6 weeks portpartum
Title
Incidence of Maternal ICU Admission
Time Frame
From randomization through 6 weeks postpartum
Title
Incidence of Composite Neonatal Morbidity Outcomes
Description
Apgar score <5 at 5 min, arterial cord pH <7.0 or base deficit >12 mmol/dL, perinatal death
Time Frame
Within 6 weeks of delivery
Title
Incidence of NICU Admission
Time Frame
Within 6 weeks of delivery
Title
Maternal Length of Stay
Description
Duration of hospitalization for delivery
Time Frame
Within 6 weeks of delivery
Title
Neonatal Length of Stay
Description
Duration of birth hospitalization
Time Frame
Within 6 weeks of delivery
Title
Perception of the Labor, Birth, and Postpartum Experience
Description
Patient perception as measured using the validated Childbirth Perception Scale. This is a 12-item instrument developed to assess a patient's perception of the labor and delivery experience. Each item is formatted on a four-point scale ranging from 0 to 3. The overall range in total score is 1-36 with higher scores indicating a less positive perception.
Time Frame
Assessed within 12-96 hours after delivery
Title
Labor Agentry Score
Description
Patient perception of labor agentry as measured using validated Labor Agentry Scale. This 29-item tool was developed to assess a patient's expectancies and experiences with control in labor. Each item is scored 1 to 7. Overall total score can range from 29-201 with higher scores indicated greater perceived control during childbirth.
Time Frame
Assessed within 12-96 hours after delivery
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Nulliparity
Maternal age >18 years
Gestational age ≥37w0d
Induction of labor, defined as initiation of labor with medication or intracervical Foley catheter in a patient without observed spontaneous cervical change and <6 contractions per hour (average of one contraction every 10 minutes) at the time of initial presentation. Women with prelabor rupture of membranes (PROM) can be included if the other criteria are also met with regards to cervical dilation and contractions.
Singleton gestation
Cephalic presentation
Indication for oxytocin use in the first stage of labor
No contraindication to labor or vaginal delivery
Pre-pregnancy BMI ≥30 kg/m2 based on patient report and confirmed by pre-pregnancy or first trimester weight as recorded in the medical record
Cervical dilation ≤4 cm at time of initiation of induction
Exclusion Criteria:
Fetal demise
Major fetal congenital malformation or known chromosomal abnormality
Prior uterine surgery (e.g., cesarean, myomectomy)
Non-reassuring fetal wellbeing as indication for induction
Intraamniotic infection suspected or diagnosed prior to randomization
Non-English
Multifetal gestation
Gestational age <37 weeks
Spontaneous labor
Cervical dilation > 4 cm at initiation of induction
Initiation of oxytocin in the second stage of labor
Use of oxytocin prior to randomization or planned use of oxytocin with foley catheter for cervical ripening
Fetal malpresentation
Estimated fetal weight >4500 g in a patient with diabetes, or estimated fetal weight >5000 g in a non-diabetic patient
Abnormal placentation (e.g. previa, suspected placenta accreta spectrum)
Physician/provider or patient refusal
Facility Information:
Facility Name
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Pilot Study: High Versus Low Oxytocin Dosing for Induction of Labor in Pregnant Patients With Obesity
We'll reach out to this number within 24 hrs